Journal of Neuro-Oncology

, Volume 82, Issue 1, pp 81–83

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

Authors

    • Department of Interdisciplinary OncologyH. Lee Moffitt Cancer Center and Research Institute
  • Michael J. Glantz
    • Department of Neurology and OncologyUniversity of Massachusetts Medical Center
  • Lisa Chalmers
    • Department of Interdisciplinary OncologyH. Lee Moffitt Cancer Center and Research Institute
  • Alixis Van Horn
    • Department of Neurology and OncologyUniversity of Massachusetts Medical Center
  • Andrew E. Sloan
    • Department of Interdisciplinary OncologyH. Lee Moffitt Cancer Center and Research Institute
Clinical-Patient Studies

DOI: 10.1007/s11060-006-9241-y

Cite this article as:
Chamberlain, M.C., Glantz, M.J., Chalmers, L. et al. J Neurooncol (2007) 82: 81. doi:10.1007/s11060-006-9241-y

Abstract

Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma. In 51 consecutive patients treated according to this regimen, 7 patients (14%) manifested surgically confirmed early necrosis without evidence of recurrent tumor. This observation suggests that daily TMZ may represent a potent radiosensitizing regimen.

Keywords

GlioblastomaTemodarRadiotherpy

Copyright information

© Springer Science+Business Media B.V. 2006